|Bid||142.00 x 100|
|Ask||0.00 x 0|
|Day's Range||152.16 - 153.03|
|52 Week Range||120.38 - 154.66|
|PE Ratio (TTM)||63.03|
|Expense Ratio (net)||0.10%|
On September 20, 2016, Regeneron (REGN) entered into a partnership with Teva Pharmaceutical (TEVA) for the development and commercialization of Fasinumab in the US.
Sage Therapeutics (SAGE) is a clinical-research-based biopharmaceutical company focused on developing drugs for life-threatening central nervous system disorders.
Analysts estimate a 0.1% decline in Merck's revenues to ~$10.5 billion in 3Q17.